石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

已收盘 11-20 16:08:15

5.210

+0.030

+0.58%

最高5.260	最低5.120	成交量5,741万
今开5.130	昨收5.180	日振幅2.70%
总市值609.36亿	流通市值609.36亿	总股本116.96亿
成交额2.99亿	换手率0.49%	流通股本116.96亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":5.21,"timestamp":1732090095011,"preClose":5.18,"halted":0,"volume":57405372,"delay":0,"floatShares":11696000000,"shares":11696000000,"eps":0.5312274,"marketStatus":"已收盘","marketStatusCode":5,"change":0.03,"latestTime":"11-20 16:08:15","open":5.13,"high":5.26,"low":5.12,"amount":298645103,"amplitude":0.027027,"askPrice":5.21,"askSize":280000,"bidPrice":5.2,"bidSize":708000,"shortable":3,"etf":0,"ttmEps":0.46886237296577926,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732152600000},"adr":0,"listingDate":772128000000,"adjPreClose":5.18,"dividendRate":0.055299,"openAndCloseTimeList":[[1732066200000,1732075200000],[1732078800000,1732089600000]],"volumeRatio":1.241795,"impliedVol":0.4212,"impliedVolPercentile":0.8381,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK"},"requestUrl":"/m/hq/s/01093/wiki","defaultTab":"wiki","newsList":[{"id":"2484151860","title":"石药集团：Q3业绩承压，新品待发力 5.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484151860","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484151860?lang=zh_cn&edition=full","pubTime":"2024-11-20 13:33","pubTimestamp":1732080825,"startTime":"0","endTime":"0","summary":"【11 月 20 日，交银国际发布研究报告称】石药集团第三季各业务板块压力巨大，收入及净利润分别下降 17.8%和 50.4%。期间，成药业务收入降低 20%，原料药及功能性食品收入也下滑。管理层预计集团今年底至明年将有 6 款新产品上市，能带动明年 BD 以外的经营收入实现正增长，且随着创新管线全力推进，研发费用将有双位数增长。交银国际指出，石药的 BD 即将进入丰收期，集团预计未来每年至少产生两个对外授权交易，规划均有望超越与阿斯利康的交易。该行下调集团目标价至 5.8 港元，维持“中性”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120142649abd12b16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120142649abd12b16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","LU1226287529.USD","IE0008369823.USD","LU1993786604.SGD","LU1008478684.HKD","LU0501845795.SGD","IE00BZ08YS42.EUR","IE00B031HY20.USD","LU0880133367.SGD","SG9999004220.SGD","LU1960683339.HKD","LU1807302812.USD","LU1226287792.SGD","IE00BZ08YR35.GBP","LU1226288253.USD","IE00BZ08YT58.USD","BK1521","LU0072913022.USD","LU1226287875.USD","BK1191","BK1515","LU1951186391.HKD","IE00B5MMRT66.SGD","LU1152091168.USD","LU1152091754.HKD","LU0326950275.SGD","LU0140636845.USD","IE0008368742.USD","IE00B543WZ88.USD","LU0067412154.USD","LU1226288170.HKD"],"gpt_icon":0},{"id":"2484713608","title":"《大行》大摩降石药(01093.HK)目标价至6.6元  下调每股盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=2484713608","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484713608?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:39","pubTimestamp":1732070340,"startTime":"0","endTime":"0","summary":"摩根士丹利发表报告指出，石药集团(01093.HK) 披露第三季业绩后，该行对其2024至2026年每股盈利预测下调8%至13%，反映带量采购对多美素(Duomeisu)及津优力(Jinyouli)的影响更大，以及恩必普(NBP)增长乏力。该行认为，虽然石药第三季业绩远逊预期，但与Lp(a)抑制剂许可相关的1亿美元预付款项将于第四季入账，预期将推动盈利增长。该行将石药的目标价由6.9元下调至6.6元，评级“增持”，同时调整对其营运资本及资本开支的预期。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-19 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220902171047369_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220902171047369_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1398092/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01093"],"gpt_icon":0},{"id":"2484594823","title":"营收利润双双下滑引得各大机构纷纷下调目标价，石药集团还有“船桨摆渡”吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2484594823","media":"医药研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484594823?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:52","pubTimestamp":1732017143,"startTime":"0","endTime":"0","summary":"财报显示，今年前三季度，石药集团收入为226.86亿元，同比下跌4.9%；股东应占溢利达到37.78亿元，同比下降15.9%。从研发动作来看，石药集团还是展现出比较猛的势头。比如，10月7日，石药集团宣布与阿斯利康订立独家授权协议。根据协议条款，石药集团同意授予阿斯利康在全球开发、制造及商业化脂蛋白抑制剂YS2302018及相关产品的独家授权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119195906a245a2b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119195906a245a2b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093"],"gpt_icon":0},{"id":"2484891414","title":"石药集团第三季度业绩下滑明显，创新药转型任重而道远","url":"https://stock-news.laohu8.com/highlight/detail?id=2484891414","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484891414?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:04","pubTimestamp":1732014272,"startTime":"0","endTime":"0","summary":"就在三天前，石药集团公布2024年前三季度业绩，报告期内，收入为人民币226.86亿元，较去年同期下跌4.9%，主要受到成药业务收入下跌的影响。进入第三季度，石药集团对旗下创新药业务的内部整合持续。在抗肿瘤治疗领域，石药集团第三季度和前三季度收入分别较去年同季和同期下跌31.2%和17.6%。在前三季度，集合石药集团创新药板块的新诺威同样出现营收净利双降。在近一年时间内，新诺威已两次出手并购石药集团旗下创新药企。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119191321abcf0666&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119191321abcf0666&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","LU1226288170.HKD","LU0067412154.USD","LU1226287529.USD","IE00B543WZ88.USD","BK1191","LU1960683339.HKD","IE0008369823.USD","LU0880133367.SGD","LU1807302812.USD","LU1226288253.USD","BK1521","IE00BZ08YR35.GBP","LU0140636845.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU1008478684.HKD","LU1226287792.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","LU1951186391.HKD","LU1152091754.HKD","IE00B031HY20.USD","LU1152091168.USD","BK1161","IE00BZ08YT58.USD","BK1515","IE0008368742.USD","LU0501845795.SGD","LU1993786604.SGD","BK1574","SG9999004220.SGD","LU0072913022.USD","06978"],"gpt_icon":0},{"id":"2484914974","title":"石药集团回购573万股，金额为2952万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484914974","media":"财中社","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484914974?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:02","pubTimestamp":1732014138,"startTime":"0","endTime":"0","summary":"财中社11月19日电石药集团（01093）发布公告，披露截至2024年11月19日，公司已发行股份总数保持在116.96亿股，公司在11月19日回购了573万股普通股，占已发行股份（不包括库存股份）的0.049%。在此次回购中，11月19日的回购交易总金额为2952万港元，回购股份的目的为拟注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411193244402286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0326950275.SGD","LU1951186391.HKD","IE0008369823.USD","LU1152091754.HKD","SG9999004220.SGD","IE00B543WZ88.USD","IE0008368742.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","BK1521","LU0072913022.USD","IE00BZ08YT58.USD","LU1960683339.HKD","LU1226287792.SGD","LU0140636845.USD","IE00BZ08YR35.GBP","LU1226288253.USD","LU1993786604.SGD","LU1152091168.USD","IE00B031HY20.USD","LU0880133367.SGD","IE00BZ08YS42.EUR","BK1191","LU1226287875.USD","LU1226288170.HKD","LU1807302812.USD","01093","BK1515","LU0067412154.USD","LU1226287529.USD","LU1008478684.HKD"],"gpt_icon":0},{"id":"2484913448","title":"石药集团(01093)11月19日斥资2952.39万港元回购573万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484913448","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484913448?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:02","pubTimestamp":1732010523,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，于2024年11月19日，该公司斥资2952.39万港元回购573万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093","LU1226288170.HKD","LU0067412154.USD","LU1226287529.USD","IE00B543WZ88.USD","BK1191","LU1960683339.HKD","IE0008369823.USD","LU0880133367.SGD","LU1807302812.USD","LU1226288253.USD","BK1521","IE00BZ08YR35.GBP","LU0140636845.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU1008478684.HKD","LU1226287792.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","LU1951186391.HKD","LU1152091754.HKD","IE00B031HY20.USD","LU1152091168.USD","IE00BZ08YT58.USD","BK1515","IE0008368742.USD","LU0501845795.SGD","LU1993786604.SGD","SG9999004220.SGD","LU0072913022.USD"],"gpt_icon":0},{"id":"2484997341","title":"【券商聚焦】中泰国际微削石药集团(01093)目标价2.3% 预计其短期内业绩仍将承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2484997341","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484997341?lang=zh_cn&edition=full","pubTime":"2024-11-19 17:03","pubTimestamp":1732006996,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际发研指，石药集团 团前三季度收入同比下跌4.9%至226.86亿元，股东应占溢利同比下跌15.9%至37.8亿元，其中第三季度收入与股东净利润分别同比下滑17.8%与51.5%，总体情况大致符合公司的盈利预告。2）恩必普与玄宁上市已近20年，在医保控费趋紧及市场竞争加剧的情况下，该行认为短期内销售收入大幅回升的可能性不高。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948019","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"gpt_icon":0},{"id":"2484993630","title":"大华继显：下调石药集团目标价至5.5港元 对其增长前景持审慎看法","url":"https://stock-news.laohu8.com/highlight/detail?id=2484993630","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484993630?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:31","pubTimestamp":1732001510,"startTime":"0","endTime":"0","summary":"大华继显发表研报指，石药集团首三季业绩令人失望，收入按年下跌近5%，经调整净利润按年下跌14.6%，管理层展望第四季营收及盈利表现将持续疲弱，要到2025年才重回正面势头。考虑到医院成本控制及带量采购仍可能对集团主要产品销售增长构成压力，因此大华继显表示对石药2024至2026年增长前景仍持审慎看法，预期股份回购可能有助稳定股价，维持“持有”评级，目标价从5.8港元下调至5.5港元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-11-19/doc-incwqrfs2961851.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-11-19/doc-incwqrfs2961851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["01093"],"gpt_icon":0},{"id":"2484959892","title":"《大行》高盛降石药(01093.HK)目标价至9.17元  对新旧产品看法更审慎","url":"https://stock-news.laohu8.com/highlight/detail?id=2484959892","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484959892?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:12","pubTimestamp":1731982320,"startTime":"0","endTime":"0","summary":"高盛发表研报指，石药(01093.HK) 第三季度业绩表现与早前公布的盈警一致。石药早前表示，新药销售量增长符合其2024年医院销售额达到20亿元人民币的目标。石药管理层亦预期，2025年新产品销售额将增加约20亿元，并指2025年销售额将实现正增长，惟下调早前订立的双位数增长指引。另外，高盛将石药2025及2026财年盈利预测分别上调2.9%及0.6%。不过2026财年之后，该行对石药新旧产品看法更为谨慎，故将其石药H股目标价由9.85元下调至9.17元，维持“买入”评级。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-18 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220902171048744_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220902171048744_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397744/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01093"],"gpt_icon":0},{"id":"2484930411","title":"【券商聚焦】交银国际削石药集团(01093)目标价7.9% 指创新管线BD潜力大但短期业绩不确定性仍高","url":"https://stock-news.laohu8.com/highlight/detail?id=2484930411","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484930411?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:20","pubTimestamp":1731979221,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发研报指，石药集团 公司3Q24收入和净利润分别下滑17.8%和50.4%，多个业务板块承受较大压力。管理层预计，2024年底至2025年公司有望上市6款新产品，驱动2025年BD以外经营收入恢复正增长，而随着创新管线全速推进，研发费用则将录得双位数增速。考虑到后续股价潜在升幅有限、催化剂与风险并存，维持中性评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947952","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"gpt_icon":0},{"id":"2484647725","title":"石药集团购回573万股 每股5.153港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484647725","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484647725?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:23","pubTimestamp":1731925412,"startTime":"0","endTime":"0","summary":"财中社11月18日电石药集团 发布公告，更新了截至2024年11月18日的股份变动情况。公司已发行股份总数为116.96亿股，未发生变化，库存股份数目保持为0。公告显示，公司在2024年11月18日购回了573万股普通股，购回价为每股5.153港元，总金额为2953万港元。此次购回股份的行为是根据2024年5月28日通过的购回授权进行的。文章来源：财中社石药集团购回573万股 每股5.153港元","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118184643a242cb18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118184643a242cb18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226287875.USD","IE00B031HY20.USD","LU0880133367.SGD","LU1226288170.HKD","SG9999004220.SGD","LU0140636845.USD","LU0067412154.USD","LU1152091754.HKD","LU0072913022.USD","IE00BZ08YS42.EUR","01093","IE0008368742.USD","LU1226288253.USD","LU1152091168.USD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU1807302812.USD","LU1226287529.USD","IE00B543WZ88.USD","LU0326950275.SGD","IE00BZ08YR35.GBP","LU1226287792.SGD","BK1191","BK1515","LU1960683339.HKD","IE0008369823.USD","BK1521","IE00BZ08YT58.USD","LU1951186391.HKD","LU0501845795.SGD","LU1008478684.HKD"],"gpt_icon":0},{"id":"2484649591","title":"石药集团(01093)11月18日耗资约2952.67万港元回购573万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484649591","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484649591?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:40","pubTimestamp":1731922803,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)公布，2024年11月18日耗资约2952.67万港元回购573万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","LU1152091168.USD","LU1008478684.HKD","IE0008369823.USD","LU0501845795.SGD","BK1515","LU0880133367.SGD","LU0067412154.USD","LU0326950275.SGD","IE00B5MMRT66.SGD","LU1226287792.SGD","LU1807302812.USD","LU1951186391.HKD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU1226287529.USD","LU1226287875.USD","BK1191","LU1226288170.HKD","LU1152091754.HKD","BK1521","SG9999004220.SGD","LU1226288253.USD","01093","IE00B031HY20.USD","LU0140636845.USD","IE00BZ08YR35.GBP","IE0008368742.USD","LU1960683339.HKD","LU0072913022.USD","LU1993786604.SGD"],"gpt_icon":0},{"id":"2484461053","title":"《大行》大华继显降石药(01093.HK)目标价至5.5元  首九月业绩逊预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2484461053","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484461053?lang=zh_cn&edition=full","pubTime":"2024-11-18 16:13","pubTimestamp":1731917580,"startTime":"0","endTime":"0","summary":"大华继显发表研报指，石药集团(01093.HK) 首三季业绩令人失望，收入按年下跌近5%，经调整净利润按年下跌14.6%，管理层展望第四季营收及盈利表现将持续疲弱，要到2025年才重回正面势头。考虑到医院成本控制及带量采购仍可能对集团主要产品销售增长构成压力，因此大华继显表示对石药2024至2026年增长前景仍持审慎看法，预期股份回购可能有助稳定股价，维持“持有”评级，目标价从5.8元下调至5.5元。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-18 12:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20181203180731116_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20181203180731116_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397506/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01093"],"gpt_icon":0},{"id":"2484161259","title":"石药集团：目标价降至 8.16 港元 短期承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2484161259","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484161259?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:33","pubTimestamp":1731915225,"startTime":"0","endTime":"0","summary":"【华泰证券下调石药集团目标价至 8.16 港元】石药集团成药短期承压，其首三季公告收入及净利润为 226.9 亿及 37.8 亿元，按年分别跌 4.9%和 15.9%，符合此前预告。第三季收入和净利润分别按年跌 17.8%和 50.4%，主因受京津冀集采影响，肿瘤产品销售承压，神经/心血管线部分产品院内处方受限，原料药、保健品价格和需求收缩。该行预计今年公司内生收入及利润仍受压。展望明年，虽有第一季恩必普库存压力，以及多美素年内全国集采影响，考虑新品进入医保加速放量，以及潜在 BD 收入贡献，看好明年收入和利润正增长，维持“买入”评级，目标价由 9.79 港元降至 8.16 港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118154024a2423002&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118154024a2423002&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093"],"gpt_icon":0},{"id":"2484110096","title":"《大行》瑞银降石药(01093.HK)目标价至8元  关注额外授权交易以抵销成品药面临多重挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2484110096","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484110096?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:26","pubTimestamp":1731914760,"startTime":"0","endTime":"0","summary":"瑞银发表研报指，石药集团今年第三季度营收按年跌17.8%，分别低于市场及该行预期各16%及20%；归属于母公司净利润下跌50.4%，分别低于市场及该行预期42%及48%。并就重点药品降价因素削减对石药的销售费用预测。该行关注石药额外授权交易以抵销成品药面临多重挑战，将其2024至2026财年每股盈利预测下调18%、23%及22%，并将其目标价由9.1元下调至8元，给予“买入”评级。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180202161552248_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180202161552248_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397480/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01093"],"gpt_icon":0},{"id":"2484116156","title":"花旗：下调石药集团目标价至9港元 第三季度销售表现疲弱","url":"https://stock-news.laohu8.com/highlight/detail?id=2484116156","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484116156?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:07","pubTimestamp":1731913620,"startTime":"0","endTime":"0","summary":"花旗发表研报指，石药集团今年第三季度销售表现疲弱。惟公司管理层预计，创新药将于2025财年贡献20亿元的增量收入，并实现收入正增长。花旗认为，石药在创新方面有巨大努力及进步。公司管理层早前预计，公司旗下药品于2025年将获得更多中国国家药监局药品审评中心的批准，至于美国食品药物管理局(FDA)亦预计将于2024或2025财年批准两款药物。另外，花旗将石药2024至2026财年营收预测分别下调6.1%、8.5%及8.8%；每股盈利预测分别下调9.9%、17.7%及18.2%，并将其目标价由10港元下调至9港元，维持“买入”评级。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张倩","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-11-18/doc-incwnnhm3550081.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-11-18/doc-incwnnhm3550081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01093"],"gpt_icon":0},{"id":"2484661981","title":"【券商聚焦】招银国际削石药集团(01093)目标价3.9% 指其老产品销售前景仍具挑战性","url":"https://stock-news.laohu8.com/highlight/detail?id=2484661981","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484661981?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:04","pubTimestamp":1731913465,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际发研报指，石药集团 3Q24业绩未达预期。2024年前九个月，石药集团总收入下降3.5%至226.9亿元人民币，归母净利润下降15.9%至37.8亿元人民币。3Q24毛利率降至67.7%，主要受“3+N”联盟省级带量采购的影响。前三季度，公司销售费用率微降至29.2%，研发费用增至38.8亿元人民币。该行指，公司的老产品销售前景仍具挑战性，新产品助力缓解压力。该行预计2024年/2025年公司收入和归属净利润将分别下降6.3%/2.0%和17.1%/5.8%。维持“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947917","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"gpt_icon":0},{"id":"2484131376","title":"华泰证券：下调石药集团目标价至8.16港元 成药短期承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2484131376","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484131376?lang=zh_cn&edition=full","pubTime":"2024-11-18 14:35","pubTimestamp":1731911739,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1226287875.USD","SG9999004220.SGD","IE00BZ08YT58.USD","IE00B031HY20.USD","LU1152091168.USD","BK1515","01093","LU1960683339.HKD","LU1993786604.SGD","LU0880133367.SGD","IE0008368742.USD","IE00B5MMRT66.SGD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU1226287529.USD","LU1226288170.HKD","LU1226288253.USD","LU1008478684.HKD","BK1521","LU0326950275.SGD","IE00B543WZ88.USD","LU0067412154.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","IE0008369823.USD","LU1951186391.HKD","LU1152091754.HKD","BK1191","HTSC.UK","LU0072913022.USD","LU1807302812.USD","LU0140636845.USD"],"gpt_icon":0},{"id":"2484661358","title":"华泰证券：下调石药集团目标价至8.16港元 成药短期承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2484661358","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484661358?lang=zh_cn&edition=full","pubTime":"2024-11-18 14:30","pubTimestamp":1731911400,"startTime":"0","endTime":"0","summary":"华泰证券发表报告指，石药集团成药短期承压，其首三季公告收入及净利润为226.9亿及37.8亿元，按年分别跌4.9%和15.9%，符合此前预告。第三季收入和净利润分别按年跌17.8%和50.4%，主因受京津冀集采影响，肿瘤产品销售承压；神经/心血管线部分产品院内处方受限；原料药、保健品价格和需求收缩。该行预计今年公司内生收入及利润仍受压。展望明年，虽有第一季恩必普库存压力，以及多美素年内全国集采影响，考虑新品进入医保加速放量，以及潜在BD收入贡献，看好明年收入和利润正增长，维持“买入”评级，目标价由9.79港元降至8.16港元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张倩","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-11-18/doc-incwnfyr0439914.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-11-18/doc-incwnfyr0439914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01093"],"gpt_icon":0},{"id":"2484618026","title":"《大行》华泰证券降石药(01093.HK)目标价至8.16元  成药短期承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2484618026","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484618026?lang=zh_cn&edition=full","pubTime":"2024-11-18 14:16","pubTimestamp":1731910560,"startTime":"0","endTime":"0","summary":"华泰证券发表报告指，石药集团成药短期承压，其首三季公告收入及净利润为226.9亿及37.8亿元人民币，按年分别跌4.9%和15.9%，符合此前预告。第三季收入和净利润分别按年跌17.8%和50.4%，主因受京津冀集采影响，肿瘤产品销售承压；神经/心血管线部分产品院内处方受限；原料药、保健品价格和需求收缩。该行预计今年公司内生收入及利润仍受压。目标价由9.79元降至8.16元。沽空资料截至 2024-11-18 12:25。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397452/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01093"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.03},{"period":"1month","weight":-0.1902},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.174},{"period":"1year","weight":-0.2422},{"period":"ytd","weight":-0.2672}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":-0.0548},{"period":"3month","weight":0.1307},{"period":"6month","weight":0.0421},{"period":"1year","weight":0.1061},{"period":"ytd","weight":0.1535}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。该公司通过三个分部运营其业务。成药分部从事研发、生产及销售药品以及授权业务。原料产品分部从事生产及销售粉状维生素C及抗生素产品。功能食品及其他分部从事制造及销售功能食品产品（包括咖啡因食物添加剂、无水葡萄糖、阿卡波糖及维生素C含片）、提供医疗服务及其他。该公司的产品治疗领域包括神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等其他领域。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.007828},{"month":2,"riseRate":0.733333,"avgChangeRate":0.098085},{"month":3,"riseRate":0.466667,"avgChangeRate":0.019763},{"month":4,"riseRate":0.6,"avgChangeRate":0.056385},{"month":5,"riseRate":0.6,"avgChangeRate":0.038129},{"month":6,"riseRate":0.333333,"avgChangeRate":0.004615},{"month":7,"riseRate":0.354839,"avgChangeRate":0.000119},{"month":8,"riseRate":0.419355,"avgChangeRate":0.009776},{"month":9,"riseRate":0.516129,"avgChangeRate":0.002662},{"month":10,"riseRate":0.580645,"avgChangeRate":0.016021},{"month":11,"riseRate":0.451613,"avgChangeRate":0.006068},{"month":12,"riseRate":0.5,"avgChangeRate":-0.014172}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}